In addition to the ALINA study, we are the first to report data on postoperative adjuvant treatment with alectinib in Chinese patients with ALK-positive NSCLC, demonstrating consistent efficacy and superior safety. The gene discussed is ALK; the disease is non-small cell lung carcinoma.